# Trade Mark Journal No.2026/034 21 August 2026

## WO0000001931431 (5)

Office of origin: United States of America

Date of International Registration:5 June 2026
Date of designation in the UK: 5 June 2026

International priority date claimed: 3 June 2026 (United States of America) (99862585)

Class 5
  Pharmaceutical preparations for the treatment of immune system related diseases and disorders, complement-mediated diseases and disorders, and neurological diseases and disorders; pharmaceutical preparations for the treatment of Guillain-Barré syndrome.

Annexon, Inc.

Representative: Joshua S. Jarvis, Esq. Foley Hoag LLP, 155 Seaport Boulevard,, Seaport West, Boston MA 02210-2600, UNITED STATES OF AMERICA